Zobrazeno 1 - 10
of 11
pro vyhledávání: '"P Rovira Torres"'
Publikováno v:
Docomomo Journal, Iss 71 (2024)
This work presents the first detailed study of the construction and materials of the Stockholm Public Library. As the building undergoes a rare period of maintenance and renovation, the floors and walls of the library are examined from three perspect
Externí odkaz:
https://doaj.org/article/b0f41785a90744e09a9484b84116d88a
Publikováno v:
Urban Planning, Vol 5, Iss 4, Pp 289-300 (2020)
This article discusses digital geographies by tracing, mapping, and revealing a series of spaces bounded by a multiplex digital infrastructure. By proposing ‘descriptivism’ as a complementary approach to digital mapping, this work discloses the c
Externí odkaz:
https://doaj.org/article/0de6106dfa67454f8a45c3e787e11386
Autor:
Ana Gomez-Lobon, Joaquin Serrano Lopez De Las Hazas, Francisco Javier Fanjul Losa, Pilar Rovira Torres, Ana Vanrell Ballesteros, Antonio Payeras Cifre, Melchor Riera Jaume
Publikováno v:
HIV & AIDS Review. International Journal of HIV-Related Problems, Vol 18, Iss 2, Pp 100-106 (2019)
Externí odkaz:
https://doaj.org/article/f8205c41e3ad4b7d8c5cb2b5e666485c
Publikováno v:
Urban Planning, 5, 4, 289-300, Digital Geographies and the City
This article discusses digital geographies by tracing, mapping, and revealing a series of spaces bounded by a multiplex digital infrastructure. By proposing 'descriptivism' as a complementary approach to digital mapping, this work discloses the city
Externí odkaz:
https://www.ssoar.info/ssoar/handle/document/71914
Autor:
L García Basas, C Varon-Galcera, P Garcia Ortega, E Serramontmany Morante, S Gimenez Giner, M Carreres Prieto, P Rovira Torres, I Cidoncha Muñoz, MQ Gorgas Torner
Publikováno v:
Section 5: Patient safety and quality assurance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cb0165ecbead9cfd3eb9e458b0750b20
https://doi.org/10.1136/ejhpharm-2023-eahp.284
https://doi.org/10.1136/ejhpharm-2023-eahp.284
Autor:
P Garcia Ortega, E Serramontmany Morante, L Garcia Basas, P Latorre García, P Rovira Torres, L Manos Pujol, I Cidoncha Muñoz, MQ Gorgas Torner
Publikováno v:
Section 5: Patient safety and quality assurance.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9417ee06523b344ef3cdcba1294fdd6e
https://doi.org/10.1136/ejhpharm-2022-eahp.331
https://doi.org/10.1136/ejhpharm-2022-eahp.331
Autor:
P Garcia Ortega, E Serramontmany Morante, L Garcia Basas, P Latorre Garcia, P Rovira Torres, L Maños Pujol, I Cidoncha Muñoz, MQ Gorgas Torner
Publikováno v:
Section 4: Clinical pharmacy services.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7800956035f15ca0553393987be7072e
https://doi.org/10.1136/ejhpharm-2022-eahp.219
https://doi.org/10.1136/ejhpharm-2022-eahp.219
Autor:
JR Urgeles Planella, P Rovira Torres, MM Santandreu Esterlich, M Gomez Zamora, O. Delgado Sánchez, Maximiliano Ortiz, E Rodriguez Campos, A Jimenez Portilla, A Gomez Lobon
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background Alirocumab and Evolocumab are proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9-I) that have been authorised by the Autonomous Health Service under the following conditions: uncontrolled familial hypercholesterolaemia (FH) wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64c33e872c9137f4abdeac27984cc376
https://doi.org/10.1136/ejhpharm-2019-eahpconf.176
https://doi.org/10.1136/ejhpharm-2019-eahpconf.176
Autor:
P Rovira Torres, M Castro Manzanares, O. Delgado Sánchez, ML Sastre Martorell, MM Santandreu Estelrich, C Perello Alomar, J Gines Rubio, F. do Pazo Oubiña
Publikováno v:
Eur J Hosp Pharm
Background Cardiovascular (CV) toxicity is a potential complication of various anticancer therapies. Although targeted therapies are considered less toxic than classic chemotherapy agents, serious CV complications have been described and longer follo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d04de4e83ddcf27431f7a30c906477b
https://europepmc.org/articles/PMC7535410/
https://europepmc.org/articles/PMC7535410/
Autor:
P Rovira Torres, C Perello Alomar, M Castro Manzanares, M Gomez Zamora, A Gomez Lobon, M Ortiz, O. Delgado Sánchez, MM Santandreu Esterlich
Publikováno v:
Eur J Hosp Pharm
Background Secukinumab is a recently approved interleukin 17A inhibitor indicated for the treatment of patients with plaque psoriasis, psoriatic arthritis and ankylosing spondylarthritis. Purpose The aim of the study was to assess the early effective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dbfdc45e0ce0fd093b63ec697a9cb28
https://europepmc.org/articles/PMC7535515/
https://europepmc.org/articles/PMC7535515/